EXELDERM (sulconazole nitrate) by Journey Medical is clinical pharmacology sulconazole nitrate is an imidazole derivative that inhibits the growth of the common pathogenic dermatophytes including trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis. Approved for tinea cruris, tinea corporis caused by trichophyton rubrum, trichophyton mentagrophytes and 2 more indications. First approved in 1985.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
EXELDERM (sulconazole nitrate) is a topical imidazole antifungal solution approved in 1985 for treating tinea cruris and tinea corporis caused by common dermatophytes. It works by inhibiting fungal growth through disruption of ergosterol biosynthesis and has demonstrated safety with no evidence of contact sensitization or phototoxicity.
Product is in late-stage maturity with minimal prescription volume (188 claims in 2023), indicating a small, stable but contracting team focused on maintenance rather than growth.
CLINICAL PHARMACOLOGY Sulconazole nitrate is an imidazole derivative that inhibits the growth of the common pathogenic dermatophytes including Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis. It also inhibits the organism responsible for tinea…
Worked on EXELDERM at Journey Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moEXELDERM offers limited career growth potential due to its LOE-approaching status, minimal prescription volume (188 claims), and highly commoditized market. Roles available are primarily defensive in nature—protecting price, managing generic competition, and maintaining market access rather than launching or expanding the franchise.